This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.
NEOGEN (NEOG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
NEOGEN's (NEOG) segmental revenues improve for the fiscal first quarter on strong sales of cleaners, disinfectants and sanitizers.
Thermo Fisher Expands Lab Plastic Making for Coronavirus Support
by Zacks Equity Research
Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.
Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Brainsway (BWAY) Jumps: Stock Rises 7.5%
by Zacks Equity Research
Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Why Bio-Rad Laboratories (BIO) Could Be Positioned for a Surge
by Zacks Equity Research
Bio-Rad Laboratories (BIO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Will Bio-Rad (BIO) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
by Zacks Equity Research
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.
Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 23.85% and 1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Jul 30: BAX, SYK & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.
New GERM ETF Launched to Tap the Growing Biotech Sector
by Sweta Killa
GERM invests in the hottest emerging biotechnology trends.
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.
Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 36.43% and 4.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bio-Rad Laboratories (BIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.
Bio-Rad Launches Serology Test to Detect Coronavirus Antibody
by Zacks Equity Research
Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.
Bruker Inks Deal to Distribute Coronavirus Detection Test
by Zacks Equity Research
The agreement would make Bruker (BRKR) a key player in coronavirus diagnosis.
Bio-Rad, Biodesix Partner to Get EUA for Coronavirus Test
by Zacks Equity Research
Bio-Rad (BIO) inks partnership deal with Biodesix to receive a EUA for a ddPCR test.
Bio-Rad's ddPCR System Detects Coronavirus More Accurately
by Zacks Equity Research
Bio-Rad's (BIO) ddPCR System shows better sensitivity and precision in the detection of SARS-CoV-2, unlike existing qPCR tests.
Coronavirus Testing Players Gain Momentum: 3 Stocks in Focus
by Sriparna Ghosal
There are several key diagnostic testing laboratory and biotech players whose prospects seem bright on account of rigorous work on developing diagnostic testing for the coronavirus.